Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 657,800 | 672,245 | 866,394 | 1,073,228 | 575,558 |
| Marketable Securities | 1,399,707 | 1,398,430 | 1,326,012 | 1,192,101 | 1,535,055 |
| Receivables | 220,635 | 219,434 | 237,963 | 184,513 | 142,271 |
| Inventories | 100,453 | 131,879 | 128,962 | 115,489 | 88,976 |
| TOTAL | $2,524,047 | $2,541,018 | $2,692,247 | $2,690,847 | $2,471,638 |
| Non-Current Assets | |||||
| PPE Net | 527,474 | 523,032 | 523,494 | 514,821 | 508,201 |
| Investments And Advances | 49,388 | 49,388 | 49,390 | 49,389 | 49,390 |
| Other Non-Current Assets | 301,487 | 278,502 | 281,228 | 280,198 | 301,188 |
| TOTAL | $878,349 | $850,922 | $854,112 | $844,408 | $858,779 |
| Total Assets | $3,402,396 | $3,391,940 | $3,546,359 | $3,535,255 | $3,330,417 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 59,746 | 62,237 | 98,094 | 40,572 | 52,418 |
| Accrued Expenses | 598,530 | 508,599 | 545,460 | 510,579 | 421,243 |
| Other current liabilities | 33,650 | 23,706 | 40,289 | 35,851 | 28,496 |
| TOTAL | $788,639 | $673,391 | $767,915 | $772,791 | $657,685 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | N/A | 677,723 |
| Deferred Revenues | 54,639 | 35,794 | 42,105 | 144,208 | 114,292 |
| Other Non-Current Liabilities | 2,827,759 | 2,786,532 | 2,742,876 | 2,697,172 | 1,643,628 |
| TOTAL | $3,021,888 | $2,977,789 | $2,936,667 | $2,830,102 | $2,496,692 |
| Total Liabilities | $3,810,527 | $3,651,180 | $3,704,582 | $3,602,893 | $3,154,377 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 125,001 | 124,526 | 124,131 | 123,028 | 120,027 |
| Common Shares | 1,250 | 1,243 | 1,240 | 1,230 | 1,210 |
| Retained earnings | -7,019,474 | -6,743,450 | -6,569,349 | -6,361,856 | -5,955,936 |
| Other shareholders' equity | -37,080 | -39,124 | -44,654 | -43,783 | -42,224 |
| TOTAL | $-408,131 | $-259,240 | $-158,223 | $-67,638 | $176,040 |
| Total Liabilities And Equity | $3,402,396 | $3,391,940 | $3,546,359 | $3,535,255 | $3,330,417 |